NCT05342792招募中3 期
Metronomic Capecitabine With or Without Tislelizuamb (PD-1 Antibody) as Adjuvant Therapy in High-risk Non-metastatic Nasopharyngeal Carcinoma: a Multicentre, Open-label, Randomised Phase 3 Trial
Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 556 人开始时间: 2022年4月17日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 556
- 试验地点
- 1
- 主要终点
- failure-free survival
研究概览
简要总结
This trial is aimed to investigate whether additional adjuvant PD-1 antibody treatment could improve survival in high-risk nasopharyngeal carcinoma compared to metronomic capecitabine alone.
详细描述
In this multicenter, randomised controlled, phase 3 trial, patients with T4N+/TanyN2-3 (AJCC/UICC 8th system), or non-metastatic nasopharyngeal carcinoma with pretreatment EBV DNA > 4000 copies/ml, will be randomized in a 1:1 ratio to receive metronomic capecitabine with or without PD-1 antibody every 3 weeks for 1 year after curative chemoradiation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age at diagnosis: 18 ~ 65 years old;
- •Pathologically confirmed primary nasopharyngeal carcinoma with "non-keratinizing carcinoma (WHO criteria)";
- •Locoregionally advanced nasopharyngeal carcinoma (T4N + or TanyN2-3M0, or TanyNanyM0 pretreatment EBVDNA ≥ 4000 copies/mL) was diagnosed according to the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) 8th edition clinical staging system.
- •Induction and concurrent chemoradiotherapy with the recommended regimen have been completed;
- •ECOG score: 0 ~ 1 points (Appendix II);
- •It is recommended to initiate adjuvant therapy within 1 month after the completion of the last radiotherapy treatment, no later than 6 weeks;
- •Normal bone marrow function: white blood cell count > 4 × 109/L, hemoglobin concentration > 90 g/L, platelet count > 100 × 109/L;
- •Normal liver and kidney function: total bilirubin ≤ 1.5 times the upper limit of normal; aspartate aminotransferase and/or alanine aminotransferase ≤ 2.5 times the upper limit of normal; alkaline phosphatase ≤ 2.5 times the upper limit of normal; creatinine clearance ≥ 60 mL/min;
- •Subjects must sign the informed consent form, and must be willing and able to comply with the visits, treatment regimen, laboratory tests and other requirements specified in the study protocol;
- •Female subjects of childbearing potential and male subjects with partners of childbearing potential must agree to use reliable contraception (e.g., condoms, regular contraceptives as directed) from screening through 1 year after treatment.
排除标准
- •Positive hepatitis B surface antigen and hepatitis B virus quantification > 1 × 1000 copies/ml, or positive anti-hepatitis C virus antibody;
- •Positive anti-HIV antibody or diagnosis of acquired immunodeficiency syndrome (i.e., AIDS);
- •Conditions such as dysphagia, chronic diarrhea, or bowel obstruction that would interfere with oral medication.
- •Patients with severe chronic or active infection that must be treated with systemic antibacterial, antifungal or antiviral therapy before randomization, including but not limited to tuberculosis infection
- •Active, known or suspected autoimmune disease (including but not limited to uveitis, enteritis, hepatitis, pituitary disease, nephritis, vasculitis, hyperthyroidism, hypothyroidism, and asthma requiring bronchiectasis). Except for type I diabetes, hypothyroidism requiring hormone replacement therapy and skin diseases not requiring systemic treatment (such as vitiligo, psoriasis or alopecia); clinicians should perform necessary history, examination and examination before enrollment for the above diseases and then exclude them;
- •Interstitial lung disease or pneumonia requiring oral or intravenous steroid therapy within 1 year;
- •Definite clinical evidence of persistent local disease or distant metastasis after chemoradiotherapy;
- •Systemic hormonal or other immunosuppressive therapy with an equivalent dose of > 10 mg prednisone/day within 28 days prior to informed consent. Subjects with systemic sex hormone doses ≤ 10 mg prednisone/day or inhaled/topical corticosteroids may be included.
- •Uncontrolled heart disease, such as: 1) heart failure, NYHA level ≥ 2; 2) unstable angina; 3) history of myocardial infarction in the past year; 4) supraventricular arrhythmia or ventricular arrhythmia requiring treatment or intervention;
- •Pregnant or lactating women (pregnancy test should be considered for sexually active women of childbearing age);
- •Previous or current other malignancy other than adequately treated non-melanoma skin cancer, carcinoma in situ of the cervix, and papillary thyroid carcinoma;
- •Receipt of live vaccines within 30 days prior to the first course of tislelizumab;
- •History of organ transplantation;
- •Other conditions that may jeopardize patient safety or compliance as assessed by the investigator, such as serious illness (including psychiatric disorders) requiring prompt treatment, severely abnormal test results, and other family or social risk factors.
- •Patients who received surgical treatment, biological therapy, or immunotherapy during or before radiotherapy;
- •Patients who are receiving or are likely to receive other chemotherapy, biological therapy, or immunotherapy History of severe hypersensitivity to other monoclonal antibodies;
- •Chemotherapy or surgery (except diagnostic) of the primary tumor or lymph nodes before standard treatment.
- •History of radiation therapy prior to standard therapy (except for non-melanoma skin cancer).
- •Patients who are known to be intolerable or sensitive to any therapeutic agents.
研究组 & 干预措施
Metronomic Capecitabine with PD-1 antibody arm
Experimental
Patients randomised to this arm will receive metronomic capecitabine (650mg/m2, BID, PO) and Tislelizuamb (200mg, iv drip, Q3W) for 1 year as adjuvant therapy, beginning 4-6 weeks after chemoradiation.
干预措施: PD-1 antibody (Drug)
Metronomic Capecitabine with PD-1 antibody arm
Experimental
Patients randomised to this arm will receive metronomic capecitabine (650mg/m2, BID, PO) and Tislelizuamb (200mg, iv drip, Q3W) for 1 year as adjuvant therapy, beginning 4-6 weeks after chemoradiation.
干预措施: Capecitabine (Drug)
Metronomic Capecitabine alone arm
Active Comparator
Patients randomised to this arm will receive metronomic capecitabine (650mg/m2, BID, PO) alone for 1 year as adjuvant therapy, beginning 4-6 weeks after chemoradiation.
干预措施: Capecitabine (Drug)
结局指标
主要结局
failure-free survival
时间窗: 3 years
calculated from the date of randomisation to the date of locoregional failure, distant failure, or death from any cause, whichever occurred first
次要结局
- overall survival(5 years)
- adverse events (AEs) and severe adverse events (SAE)(5 years)
- distant metastasis-free survival(3 years)
- locoregional recurrence-free survival(3 years)
- quality of life (QoL)(3 years)
研究者
Jun Ma, MD
Hospital Deputy Dean
Sun Yat-sen University
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative RecurrenceCholangiocarcinoma, IntrahepaticNCT04782804Fudan University30
尚未招募
不适用
Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal CancerRectal CancerNCT06504875The First Affiliated Hospital with Nanjing Medical University23
招募中
3 期
Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal CancerMicrosatellite Instability HighColorectal CancerNCT06520683Sun Yat-sen University180
招募中
3 期
Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal CancerRectal NeoplasmsNCT06017583Yong Zhang,MD48
Unknown
1 期
Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical CarcinomaCervical Squamous Cell CarcinomaNCT05013268Ruijin Hospital15